Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
DBV Technologies (Nasdaq:DBVT) announced the provisional appointment of Philina Lee, Ph.D. to its Board of Directors, effective October 30, 2025. She replaces Daniel Soland and will serve on the Board's Compensation Committee, increasing the Board to ten directors. The appointment is provisional and subject to shareholder ratification at the next annual meeting. Dr. Lee joins from Blueprint Medicines, where she led commercial operations including the launch and growth of AYVAKIT, and previously served on Fusion Pharmaceuticals' Board committees. DBV said her commercial and product-launch experience is expected to support advancement toward potential commercialization of VIASKIN Peanut for children and toddlers.
DBV Technologies (Nasdaq: DBVT) will participate in the ACAAI 2025 Annual Scientific Meeting in Orlando, November 6–10, 2025. DBV will host a Product Theater on Nov 8, 2025 (11:35 a.m.–1:00 p.m. ET) titled “Harnessing Immune Plasticity to Alter the Path of Food Allergy.”
The presentation will include a panel of allergists and details of a planned Phase 2 study assessing VIASKIN Peanut patch efficacy and safety to achieve ad lib peanut consumption in infants aged 6–12 months after a minimum of 3 years of treatment. Dr. Matthew Greenhawt will present EPOPEX end-of-study results on Nov 8 at 4:43 p.m. ET.
DBV will exhibit at booth #711, sponsor the FIT Bowl on Nov 8 (5:45–7:45 p.m. ET), and notes line-of-sight to a potential BLA filing for toddlers 1–3 years in the second half of next year under an Accelerated Approval Pathway.
DBV Technologies (Nasdaq: DBVT) announced an at-the-market sale of ADSs on October 29, 2025, raising approximately $30 million gross through Artisan via Citizens Capital Markets.
The transaction issues 2,142,860 ADSs (representing 10,714,300 ordinary shares), priced at $14.00 per ADS (subscription price €2.4063), and is expected to settle on October 31, 2025. New shares represent 6.34% of existing Euronext-listed shares and dilute existing holders by ~5.96%. Management estimates cash runway extended to end of Q4 2026; topline pediatric results and BLA timing reiterated for 4Q2025–1H/2H2026.
DBV Technologies (NASDAQ:DBVT) reported third quarter 2025 results with $69.8M cash and cash equivalents as of September 30, 2025, supporting an estimated cash runway into the third quarter of 2026. The company recorded a $102.1M net loss for the nine months ended September 30, 2025 and operating expenses of $107.0M over the same period.
Key financing actions include a 2025 PIPE (up to $306.9M) that delivered $125.5M on April 7, 2025 and potential aggregate proceeds of up to $181.4M if warrants are exercised; an ATM program of up to $150M and ~$30M gross received October 6, 2025. Management warns of substantial doubt about going concern and is pursuing additional financing options.
DBV Technologies (NASDAQ:DBVT) announced an At-The-Market sale of 2,307,692 ADSs (representing 11,538,460 ordinary shares) for gross proceeds of approximately $30 million at an at-the-market price of $13.00 per ADS (each ADS = 5 ordinary shares). The issuance price equates to a subscription price of €2.2264 per ordinary share (FX $1.1678/€1) and reflects a 3.41% discount to the prior Euronext Paris close. Settlement is expected on October 8, 2025, with ADSs admitted on Nasdaq and the new ordinary shares on Euronext Paris. The new shares represent 8.42% of existing Euronext-listed shares and imply ≈7.77% dilution on completion. A Form S-3 registration statement has been declared effective.
DBV Technologies (NASDAQ: DBVT) announced the immediate resignation of Daniel Soland from its Board of Directors. Soland, who joined the board in 2015, served on the Compensation Committee and contributed his expertise to the company's development of the VIASKIN® Peanut patch for peanut allergic children.
The Board will continue to operate with 9 remaining members while the Nomination and Governance Committee evaluates the timing and process for appointing a new member, subject to shareholder ratification at the next Annual General Meeting.
DBV Technologies (NASDAQ:DBVT) has established a new At-The-Market (ATM) Program on Nasdaq, allowing the company to sell up to $150 million of American Depositary Shares (ADS). Each ADS represents five ordinary shares, with Citizens JMP Securities acting as sales agent.
The proceeds will primarily fund activities related to the Biologics License Application (BLA) and potential launch of VIASKIN® Peanut patch for toddlers aged 1-3 years, along with advancing their VIASKIN platform development. The program could result in a maximum potential dilution of approximately 50% based on existing share capital, with sales limited to qualified investors in the pharmaceutical and biotechnology sectors.
DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Daniel Tassé will engage in a fireside chat on September 9, 2025, at 11:30am ET in New York.
The presentation will be accessible through a live webcast and will remain available for replay on the company's investor relations website for 90 days after the event.
DBV Technologies (NYSE:DBVT) has reported its monthly update on voting rights and share count as of July 31, 2025. The company disclosed a total of 136,975,159 shares outstanding, with the same number of gross voting rights. The net total of voting rights stands at 136,810,568, reflecting shares without voting rights.
This disclosure is made in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers for companies listed on NYSE Euronext Paris.
DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company specializing in food allergies and immunologic treatments, has announced the filing of its 2025 Half-Year Report with the French market authority (AMF) for the period ending June 30, 2025.
The report is available in French on the company's website under the Investors/Financial Information section, on the AMF website, and can be requested directly from DBV Technologies via mail or email.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
